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Objective: To explore the effect of PPARg agonist (rosiglitazone) on the secretion of
Th2 cytokines and the proportion of immune cell subsets in asthma mice.
Methods: Ovalbumin (OVA)-sensitized mice were used to build asthma models. Those
mice were divided into the normal control group, model group and rosiglitazone group.
Differences of the changes in lung histopathology of mice in the three groups were
observed through hematoxylin and eosin (HE) strain, and the numbers of the total cells,
eosinophils and neutrophils in BALF of mice in the three groups were compared. ELISA
and real-time PCR were employed to detect the protein levels of interleukin (IL)-5, IL-13,
IL-4 and IL-10 and mRNA level, respectively. Flow cytometry number was implied to
analyze the proportion of immune cell subsets in peripheral blood of mice.
Results: Compared with the mice in the control group, and mice of the model group, the
inﬁltration of inﬂammatory cells in BALF increased, bronchial smooth muscle became
thickened, a large amount of collagen deposited, the secretion of Th2 cytokine increased
signiﬁcantly, the ratio of regulatory T cells (Treg) decreased, the ratio of T17 cells rose
distinctly; while in mice of the rosiglitazone group, the changes of their lung histopa-
thology were improved obviously, the number of inﬁltration of inﬂammatory cells
declined, the thickened smooth muscle relieved, the deposition of collagen decreased, the
secretion of Th2 cytokine was inhibited, the ratio of Treg went up, and the increased of
the ratio of T17 cells was inhibited but still not return to normal level.
Conclusions: Rosiglitazone can regulate the proportion of Treg and Th17 cells and
inhibit the secretion of Th2 cytokines, which inhibit the airway inﬂammatory response for
asthma mice effectively.1. Introduction
Bronchial asthma is an allergic disease in respiratory system
characterized by chronic inﬂammation with an increasing inci-
dence worldwide, which severely threatens human health. The
pathogenesis of the disease has not been illuminated completely
yet [1,2]. More and more researches have pointed out that bronchial
asthma is accompanied by the activation of a large number of
immune cells including eosinophils, neutrophils, macrophages,
mast cells and T cells. The activation of immune cells induces
the synthesis and release of multiple inﬂammatory factors. The
interaction of these inﬂammatory cells and cytokines causespathology changes such as bronchiolar inﬂammation, the
hyperplasia of mucous epithelium and smooth muscle, collagen
deposition and so on [3,4]. Hence, it is of great signiﬁcance to
exploit drug to inhibit airway inﬂammatory response and explore
its mode of action for clinical treatment and research of
bronchial asthma. Peroxisome proliferator activated receptor-g
(PPARg) is an important number of the inﬂammatory signaling
pathway. Its special agonist (rosiglitazone) plays a potential role
in multiple inﬂammation-related injury models [5–7]. This study
aims to explore the effect of PPARg agonist (rosiglitazone) on
asthma mice and its inﬂuence on the secretion of Th2 cytokine
and the proportion of immune cell subsets.
2. Materials and methods
2.1. Major reagents
Ovalbumin (OVA) (Sigma, USA), rosiglitazone (batch
number: 040511, GSK, China), ELISA kits for interleukin (IL)-
5, IL-13, IL-4 and IL-10 (eBioscience) were used in this study.der the CC BY-NC-ND license (http://
Ji-Hui Yu et al./Asian Paciﬁc Journal of Tropical Medicine 2017; 10(1): 64–68 65Trizol reagent was purchased from Life (USA), reverse tran-
scription kits and SYBR Green Real-time PCR reagent was
bought from Takara. The primer was designed and compounded
by Sangon Biotech (Shanghai) Co. Ltd. 10× mice hemocyte
lysate was from BD. Cytokine staining reagents, cellular nuclei
staining reagents, Fc Block antibody, stream antibodies Foxp3-
APC, CD25-FITC, CD4-PE, IL-17-Perciﬁc blue and CD3-PE
Cy7 were all bought from eBioscience.
2.2. Animal models and drug administration
In this study, OVA-sensitized mice were used to build
asthma models. Twenty-four female mice of clean grade (6–8
weeks, 18–22 g) were provided by the Laboratory Animal Unit
of Congqing Medical University. All mice were divided into the
control group, model (OVA) group and rosiglitazone
(OVA + ROSI) group in accordance with the randomized digital
table with eight mice in each group. Mice in the OVA and
OVA + ROSI groups were given 0.1 mL sensitization liquid
OVA containing 100 mg of OVA and 31 mg of AL(OH) by
intraperitoneal injection at day 0 and day 7. Fourteen days later,
those mice were placed in transparent container, and then 2%
OVA normal saline solution was sprayed by using ultrasonic
fogging tester to trigger asthma for 30 min once per day. Be-
sides, mice in the rosiglitazone group were also treated with
5 × 10−5 mol/L of rosiglitazone simultaneously for continuous
stimulation for 7 days. In the normal control group, normal sa-
line was used to replace OVA sensitization and atomization
motivation. After the ﬁnal stimulation, the middle lobe of the
lung tissue in mice was taken out for routine parafﬁn section and
hematoxylin and eosin (HE) strain to observe the changes of
their lung histopathology. Experiments involved animals in this
study was approved by the Biomedical Ethics Committee of The
First Afﬁliated Hospital of Chongqing Medical University.
2.3. The collection and management of BALF
After mice in the three groups were anaesthetized by 0.75%
pentobarbital sodium, a transverse cutting was conducted under
the cricoid cartilage of mice in which the irrigating tube was
placed. One milliliter sterile normal saline were injected slowly
and recycled three times. The recycled liquid was centrifuged at
15000 r/min for 10 min at 4 C. The supernatant was collected
and stored at −80 C for detecting cytokines. Cell sediments
were used to counting cell numbers and RNA extraction.
2.4. BALF cell counts and classiﬁcation
After the centrifugation of BALF, 200 mL of normal saline
was used to suspend cell sediments and mix. Out of them, 20 mL
of the cell suspension liquid was mixed with 380 mL of acetic
acid. Blood cell counting board was used to count the total cells.
Besides, two pieces of cell rejection slice were prepared and
stained by Wright–Giemsa stain, respectively. Then, the
numbers of eosinophils and neutrophils were recorded. Every
specimen was responsible for at least 400 cells.
2.5. Analysis of lung histopathology in mice
Routine HE stain was conducted in sections of lung tissues of
those mice to observe their lung histopathology. Image analysissoftware Un-Scan-It 6.0 was used to test the thickness of
bronchial smooth muscle and collagen deposition in mice.
2.6. ELISA
Ebioscience ELISA kits were used to determine the contents of
IL-5, IL-13, IL-4 and IL-10 in BALF of mice, which was con-
ducted in accordance with the construction strictly. Half an hour
before the procedure, the reagent was place at room temperature
for 30 min. The specimen and gradient concentration standards
(100 mL/well) were added into a 96-well plate and then closed the
plate for incubation at 37 C for 30 min. A washer was used 4
times. Then, 100mLof biotinylated antibodywas added into every
well and the plate was sealed for incubation at 37 C for 60 min.
After washing for 4 times, 100 mL color-developing agent was
added into every well. Ten minutes later, stop buffer was added
and mixed to detect OD450. The washer and enzyme-labeled
liquid were all purchased from Biotech.
2.7. Real-time PCR
Routine Trizol method was applied to extract the total RNA
of cells. Every sample was dissolved in 10 mL RNase free water.
PrimeScript™ RT Reagent Kit with gDNA Eraser kits (Tarara)
were employed to remove genomic DNA and conduct reverse
transcription. Realtime PCR was used to detect the levels of IL-
5, IL-13, IL-4 and IL-10 and RNA levels. The expression level
of RNA was calculated by 2-DDCq method with b-actin serving
as the reference. Realtime PCR 7500 instrument was from ABI.
2.8. Flow cytometry
A total of 500mL of peripheral blood of mice were collected and
50 mL/tube of heparin was added into it for anticoagulation. Then,
3 mL 1 × hemocyte lysate was used for broken management for
3 min. After that, 10 mL pre-cooling PBS was added to terminate
dissociation. The device was centrifuged at low temperature of 4 C
with centrifuged speed of 500 g for 5 min. Cells were collected and
closed for 10 min and then stained with diolame. Antibodies CD3,
CD4andCD25were added and incubated in dark at 4 C for 30min.
After washed by PBS, it was ﬁxed for 0.5 h by ﬁxer. After nucleus-
cross management, Foxp3 and IL-17 antibody were added and also
incubated in dark at 4 C for 30 min. After washed by cleaning
mixture twice, BD cantoII ﬂow cytometerwas implied for detection
and Flow Jo6.0 software was employed for analysis and statistics.
2.9. Statistic management
Measurement data in this study were expressed by
mean ± SD and analyzed by SPSS software. Comparisons be-
tween groups were illustrated by One-way ANOVA and pair-
wise comparisons among groups were analyzed by LSD
method. P < 0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Administration of PPARg agonist (rosiglitazone)
improving airway inﬂammation response for asthma mice
Compared with the control group, the numbers of the total
cells, eosinophils and neutrophils in mice of the OVA group all
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model construction. The airway inﬂammation response in mice
of the rosiglitazone group was relieved and the their numbers of
the total cells, eosinophils and neutrophils were all lower than
those of the OVA group (Table 1, P < 0.05), but did not return
to the normal levels, since the numbers of both eosinophils and
neutrophils were all signiﬁcantly higher than those of the control
group (Table 1, P < 0.05).Table 1
Numbers of the total cell count, eosinophil cells and neutrophil cells in BALF of mice in each group as well as airway reconstruction status of mice
(n = 8).
Group Total cell count
(104/mL)
Eosinophil cell
(104/mL)
Neutrophil cell
(104/mL)
Smooth muscle layer
thickness (mm)
Collagen content (AU)
Control 11.45 ± 1.68 0.18 ± 0.01 0.13 ± 0.02 8.20 ± 1.43 28.23 ± 4.03
OVA 24.57 ± 2.85* 7.93 ± 0.56* 3.45 ± 0.40* 36.72 ± 5.04* 89.44 ± 11.07*
OVA + ROSI 13.07 ± 2.82# 3.22 ± 0.41*# 1.28 ± 0.11*# 20.39 ± 6.92*# 33.65 ± 8.79#
*Compared with the control group, P < 0.05; #Compared with the OVA group, P < 0.05.
Table 2
Levels of the cytokines in BALF in mice (n = 8).
Group IL-5 (pg/mL) IL-13 (pg/mL) IL-4 (pg/mL) IL-10 (pg/mL)
Control 34.71 ± 5.05 94.73 ± 8.09 38.37 ± 5.61 7.88 ± 2.05
OVA 94.72 ± 11.26* 277.13 ± 33.12* 79.07 ± 9.41* 44.82 ± 6.13*
OVA + ROSI 47.22 ± 5.67*# 121.64 ± 33.71*# 43.76 ± 5.82# 20.37 ± 4.22*#
*Compared with the control group, P < 0.05; #Compared with the OVA group, P < 0.05.
Table 3
The relative expression level of mRNA in cytokines and changes in Treg and Th17 cell ratio.
Group IL-5 IL-13 IL-4 IFN-g Treg (%/CD4) Th17 (%/CD4)
Control 1.02 ± 0.08 1.10 ± 0.11 0.95 ± 0.09 1.04 ± 0.21 4.72 ± 0.87 0.75 ± 0.12
OVA 86.73 ± 5.23* 114.05 ± 8.91* 44.11 ± 6.20* 15.94 ± 2.61* 2.31 ± 0.75* 4.22 ± 1.08*
OVA + ROSI 12.77 ± 3.08*# 26.71 ± 4.94*# 4.11 ± 1.02*# 3.55 ± 0.59*# 4.09 ± 0.91# 1.27 ± 0.89#
*Compared with the control group, P < 0.05; #Compared with the OVA group, P < 0.05.3.2. Inﬂuence on airway remodeling in mice
administered with rosiglitazone
The results of HE stain showed that mice in the normal
control group had normal bronchus and vascular structure
without inﬂammatory cell inﬁltration. In mice of the OVA
group, airway inﬂammatory response took place obviously,
airway smooth muscle became thickened signiﬁcantly (Table 1,
P < 0.05), mucous epithelium proliferated, a large amount of
collagen deposited in the bronchus, vascular alveolar walls and
pulmonary mesenchyme accompanied by mass inﬁltration of
inﬂammatory cells (Table 1, P < 0.05). Symptoms of mice in the
rosiglitazone group were improved, their thickened airway
smooth muscle was relieved and the deposition of collagen
reduced (Table 1, P < 0.05).
3.3. Inﬂuence of rosiglitazone on cytokines in asthma
mice
Compared with the control group, the protein levels of Th2
cytokines IL-5, IL-13, IL-4 and IL-10 and mRNA level in BALFin mice of the OVA group increased signiﬁcantly (Tables 2 and 3,
P < 0.05); while the protein levels of Th2 cytokines IL-5, IL-13,
IL-4 and IL-10 andmRNA level inmice of the rosiglitazone group
decreased as compared to those of the OVA group, which indi-
cated that the inﬂammatory response in mice was relieved.
However, only the level of IL-4 was back to its normal level, the
expressions of other Th2 cytokines were still much higher than
those of the control group (Tables 2 and 3, P < 0.05).3.4. Changes of the ratio of peripheral blood regulatory
T cells (Treg) and Th17 cells
The results of ﬂow cytometer demonstrated that Treg
accounted for 4.72% of CD4+ T cells in normal mice, while
Th17 cells accounted for less than 1%. In asthma mice of the
OVA group, the ratio of Treg declined signiﬁcantly, while the
ratio of Th17 cells rose markedly. Compared with the OVA
group, the changes of the ratio of Treg and Th17 cells in mice of
the rosiglitazone group relieved signiﬁcantly, but not returned to
the normal levels (Table 3, P < 0.05).
4. Discussion
PPARg is the transcription factor activated by ligand of the
nuclear hormone receptor superfamily, which expresses in
multiple tissues and cells. Early researches have found that
PPARg could regulate the differentiation of adipocytes and lipid
metabolism and also be closely related to the insulin resistance
in diabetes patients. Its special agonist rosiglitazone is also
approved to be used to treat diabetes mellitus type 2 [8,9]. Recent
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multiple signaling pathways of inﬂammatory responses,
participate in the production and secretion of cytokines and
play a key role in the cardiovascular system and the
development of tumors as well [10–12]. There have been
researches [13] reporting that PPARg was closely related to the
airway inﬂammatory response in mice. The results of this
study also indicated that the special agonist of PPARg,
rosiglitazone, could regulate the ratio of peripheral blood Treg
and Th17, reduce the inﬂammatory cells inﬁltration of lung
tissue, inhibit the secretion of Th2 cytokines and inhibit the
airway inﬂammatory response of asthma mice effectively.
Inﬂammatory cells inﬁltration and airway remodeling are two
important features of bronchial asthma. OVA-sensitized mice
were used to build asthma models. The results showed that the
numbers of the total inﬂammatory cell count, eosinophil cells
and neutrophil cells in BALF of mice all increased, mucous
epithelium proliferated and a large amount of collagen deposited
in the bronchus, vascular alveolar walls and pulmonary
mesenchyme, which indicated the success of model construc-
tion. In addition, we found that in mice administered with
rosiglitazone the inﬂammatory cell inﬁltration declined, their
thickened bronchial smooth muscle relieved signiﬁcantly and
the collagen deposition in the vascular alveolar walls and pul-
monary mesenchyme reduced markedly, which manifested that
rosiglitazone could inhibit the airway inﬂammatory response of
asthma mice effectively showing certain effect on the treatment
of asthma, which showed consistency with the early researches
focusing on lung injury [14,15].
Under physiological condition, the ratio of in vivo Th1/Th2
cells is in equilibrium so as to maintain normal humoral im-
munity and cell mediated immunity for the body. However, in
asthma patients, the balance of the ratio of in vivo Th1/Th2 cells
is broken with the inhibited Th1 cell function and hyperfunction
of Th2 cell function. Therefore, there are researches pointing out
that the mass production of Th2 cytokines (IL-5, IL-13, IL-4 IL-
10, etc.) plays an important role in the course of asthma [16–18].
Results of this study showed that the protein levels of Th2
cytokines IL-5, IL-13, IL-4 and IL-10 and mRNA level in
BALF in asthma mice increased signiﬁcantly, while rosiglita-
zone could markedly decrease the protein levels of IL-5, IL-13,
IL-4 and IL-10 and mRNA level, which indicated that rosigli-
tazone may relieve asthma symptoms for mice by inhibiting the
synthesis and secretion of Th2 cytokines.
Recently, there are researches reporting that Treg and Th17
cells play important roles in the development of asthma. These
two cells demonstrate antagonistic effects mutually, which has
important effect on keeping the immune state for the body [19–
21]. It was also found in our study that compared with those of
the normal mice, the proportion of Foxp3+ Treg in asthma
mice decreased signiﬁcantly, while the Th17 cells increased
markedly, which indicated that the unbalance of Treg/Th17
participated in the course of airway inﬂammation in asthma
mice. Moreover, compared with the OVA group, the ratio of
Treg in peripheral blood in mice of the rosiglitazone group
returned back and the ratio of Th17 cells declined
signiﬁcantly, which implied that rosiglitazone might further
inhibit the inﬂammation in the airways mediated by Th2 cells
by increasing the ratio of Treg in peripheral blood.In conclusion, the results of this study suggested that the
special agonist of PPARg, rosiglitazone, could relieve the
symptoms of asthma by increasing the ratio of Treg cells,
inhibiting the number of Th17 cells and suppressing the secre-
tion of Th2 cytokines.
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